Why Did Pharma Stocks Surge?

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Why Did Pharma Stocks Surge?

Jul 17, 2021

Shares of pharmaceutical companies were in demand, with stocks of Alkem Laboratories, Divi's Laboratories and Syngene International rallying up to 14% to hit record highs on BSE on Friday.

This was amid expectation of strong earnings for the quarter ended June 2021, helped by low base last year and strong demand led by the pandemic.

The BSE Healthcare Index hit a new high of 26,364.8 in intra-day trade. So far in the financial year 2021-22, the healthcare index has rallied 24% as against a 9% gain in the benchmark index.

Nifty Pharma too hit a fresh record high of 14,715 in intra-day session on National Stock Exchange (NSE).

What's driving the rally?

Indian Pharmaceutical Market (IPM) reported an increase of 37% year on year (YoY) in the first quarter of the current fiscal 2022 on a low base, due to strong demand led by pandemic and Covid drugs.

Adjusting for the low base and Covid portfolio, analysts estimate IPM growth at 15% YoY for the quarter.

According to market experts, a lower base and a revival in domestic formulations are likely to drive overall sales.

On the other hand, despite a favourable base in some select stocks, US formulations growth is expected to remain subdued amid a lack of meaningful launches, price erosion, and currency headwinds.

On the hospitals front, the second wave is likely to change the product mix more towards Covid occupancies, which is likely to impact realisations.

--- Advertisement ---
No crash, correction, or pandemic can STOP This...

At last, it's happening...

Right here in India...three hidden mega-trends are converging for the first time ever to trigger an economic boom of unparalleled proportions.

A boom so powerful - no crash, no correction, and no pandemic can STOP India from becoming the next economic superpower...

And those who take advantage of this mega shift could potentially generate massive wealth for themselves and their families in the long run.

We are talking about potential 1,000% gains...and perhaps even more over the long term.

But trust me, people who pass this opportunity will regret their decision in the years and decades to come...

So, if you want to save yourself from potential downsides of this mega shift...

...and instead, leverage on it for potential windfall gains...

Join us on 24th September at my special event...

Put your email in the box below and get your free ticket right away.
------------------------------

An overview on pharma stocks quarter performance

The fourth quarter of the financial year 2021 saw tough US business for several Indian pharma firms on a decade-low flu season.

As per a leading financial daily, Sun pharma will clock the best quarter on quarter (QoQ) growth on continued traction in specialty segment, followed by Alkem Laboratories, which would benefit from a very low base of March 2021 quarter.

Cipla's growth comes from a low base and new product launches in the quarter, Dr Reddy's growth would be driven by its healthy product launch rate.

India's second-largest drugmaker by market value, Divi's Laboratories, reported 25% jump in its net profit to Rs 4.9 bn for the quarter ended March 2021.

The company benefited from a low base in the year-ago quarter which was hit by the Covid-19 national lockdown.

Covid-19 impact powered Indian pharmaceutical industry to new heights

The domestic pharma market turnover in India has reached Rs 1.4 tn in 2019 as per the government data. This is actually an increase from Rs. 1.3 tn in 2018.

The Indian pharmaceutical industry supply for over 50% of global demand for various vaccines.

India is the third largest producer of drugs in terms of volume and vaccine production accounts to 60% global production.

--- Advertisement ---
INSIDER SECRET: An Astonishingly Easy Way to Pile Up Potentially 40-60% Gains in Just 1 Year

India's most well-connected trader with over 35 years of experience just confessed...

"This Lucrative Market Segment Could Leapfrog Over Nifty in The Next 12-16 Months"

... thanks to a massive and irreversible mega-trend fueling its growth!

In fact, he and his partner have already identified 2 spectacular stocks from this segment... which are ready to rake in potentially 40-60% gains in just 1 year... and make you big, fat profits!

The best part of them all...

Their Details Are Packed in This Special Report (Discover How to Claim it for Free)
------------------------------

The coronavirus pandemic and its resultant lockdown badly affected all major sectors of the economy, but it has come as a boon in disguise to the Indian pharmaceutical sector.

Though some part of pharmaceutical business was affected such as supply chain and import of active pharmaceutical ingredients (API) from China, Covid-19 has provided some opportunities in the pharmaceutical sector in India.

Also, due to the severe second Covid wave, Covid beds saw near 100% occupancy across the country.

The second wave of Covid-19 in the country pushed up sales of medicines and resulted in exponential growth for the pharmaceutical sector.

Building unicorns in pharma API space to make India Atma Nirbhar

API as a sector has been a neglected space within the Indian pharma, with India's share of imports from China increasing consistently from 60% in 2012 to 67% in 2020.

Understandably, the pandemic was a rude shock for most of the formulation players in early March with impending supply chain disruptions, given the overreliance on one country for many critical APIs and intermediates.

In this context, building a globally competitive and self-reliant API industry is the need of the hour.

Eroding advantage driving 'Shift-away from China'?

Over the last few years, global markets have observed a shift away from the Chinese supply driven by three critical factors - reducing cost advantage, increasing regulatory challenges and degrading supply reliability.

These issues have further aggravated by the ongoing pandemic eroding China's global competitive advantage. The foundation offering from Chinese companies is the cost advantage.

With increasing labor costs driven by standard of living and focused efforts from the government to revise select incentive structures, including taxes, is resulting in loss of cost advantage when compared to a low-cost, stable market such as India.

As customers move volume away from China, Indian API industry is likely to grow in coming years.

REVEALED: 3 "Super Smallcaps" You Didn't Know About

Equitymaster's view on the pharma sector

We reached out to Tanushree Banerjee, Co-Head of Research at Equitymaster, and editor of the premium stock recommendation service StockSelect, for her view on the pharma sector.

Here's what she has to say...

  • The second Covid wave has given a new lease of life to pharma stocks. As the sector continues to invest in capacities for new drugs, the profitability will depend on the companies' ability to seek USFDA approval for the plants.

    Or their ability to tie up with MNC pharma for producing variants of their vaccine.

How pharma stocks performed on Friday

Among individual stocks, Divis Laboratories surged 3.5% to Rs 4,765 on the BSE.

Glenmark Pharma and JB Chemicals ended the day up 4.5% and 5.6%, respectively.

On the other hand, shares of Lupin and Dr Reddys Lab ended the day up 1% and 0.2%, respectively.

Shares of Wockhardt ended the day up by 7%, while Orchid Pharma ended down by 5% on Friday.

Here's a list of pharma stocks and their performance...

    Returns
SCRIP BSE PRICE(Rs) 1 month 1 year
AARTI DRUGS 729.5 0.5% 115.9%
AJANTA PHARMA 2,154.50 11.1% 59.7%
CADILA HEALTHCARE 644.2 -1.7% 82.2%
CIPLA 975.6 -0.1% 54.3%
DIVIS LABORATORIES 4,760 8.5% 114.7%
DR. REDDYS LAB 5,407 -1.0% 35.7%
GLENMARK PHARMA 685.2 6.4% 68.3%
LUPIN 1,173 1.6% 34.4%
SUN PHARMA 689 1.7% 40.1%
TORRENT PHARMA 2,993.80 1.0% 23.7%
Source: Equitymaster

For more detailed updates, read our Indian Pharma sector report and check the latest Indian Pharma sector results.

You can also compare pharma stocks on our website.

Lupin vs Divis Laboratories

DR Reddys Lab vs Alkem Laboratories

Cipla vs Glenmark Pharma

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...

Equitymaster requests your view! Post a comment on "Why Did Pharma Stocks Surge?". Click here!

  

More Views on News

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

Apollo Hospitals' Shares Rally Over 5%, Hit Record-High on Strong Results (Views On News)

Aug 16, 2021

The company reported a 73% YoY increase in revenue driven by an uptick in the hospital and pharmacy business.

J B Chemicals & Pharma's Decent Performance Puts Stock in Focus (Views On News)

Aug 13, 2021

The company seeks to expand the market for prescription lozenges with new launches this year.

Krsnaa Diagnostics IPO Opens Tomorrow: Key Points to Consider (Views On News)

Aug 3, 2021

Krsnaa Diagnostics grey market premium is at around Rs 440 from its issue price of Rs 933-954.

Windlas Biotech IPO to Hit the Market on 4 August. Key Points to Know (Views On News)

Jul 31, 2021

Windlas Biotech IPO to open for subscription next week. Price band fixed at Rs 448-460.

More Views on News

Most Popular

All You Need to Know About Primary and Secondary Markets

A look at the various types of primary and secondary markets and the key differences between them.

Sansera Engineering IPO: Key Points to Consider (Views On News)

Sep 8, 2021

This IPO is a pure OFS and the company is looking to raise Rs 12.8 bn at the upper price band of Rs 744.

5 Stocks that Turned Rs 1 Lakh into Rs 1 Crore (Views On News)

Sep 7, 2021

Patience is one of the biggest virtues you need to have if you want to become a crorepati in the stock market.

The Top Stocks to Sell in this Bull Market (Profit Hunter)

Sep 8, 2021

When I saw the list of so-called 'value stocks' published by a leading brokerage, my worst fears came true.

5 Indian Companies that are Leading the AI Race (Views On News)

Sep 9, 2021

During the pandemic, India reported the highest increase in the use of AI at 45% compared to other major economies. AI has potential to add US$90 bn to the Indian economy by 2025.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Sep 17, 2021 (Close)

MARKET STATS